Enveric Biosciences (ENVB) Gains from Investment Securities (2018 - 2025)
Enveric Biosciences (ENVB) posted Gains from Investment Securities of -$858.0 for Q1 2025, up 76.48% sequentially from -$3648.0 in Q4 2024, and up 91.45% YoY from -$448.15 in Q1 2024.
Enveric Biosciences (ENVB) Gains from Investment Securities (2018 - 2025) Analysis & Trends
Enveric Biosciences has reported Gains from Investment Securities for 7 years, with the latest figure at -$858.0 in Q1 2025.
- Quarterly Gains from Investment Securities rose 91.45% year-over-year to -$858.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was -$858.0 (up 96.48% YoY) and the FY2025 annual result came in at -$858.0, up 96.48% from the prior year.
- Gains from Investment Securities climbed to -$858.0 in Q1 2025 per ENVB's latest filing, from -$3648.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $233821.0 in Q2 2023 and troughed at -$3.8 million in Q1 2021.
- A 5-year average of -$809540.4 and a median of -$209738.0 in 2023 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities soared 111.87% in 2023, then sank 104.62% in 2024.
- Over 5 years, Gains from Investment Securities stood at -$2.2 million in 2021, then soared by 79.12% to -$469722.0 in 2022, then surged by 55.35% to -$209738.0 in 2023, then surged by 98.26% to -$3648.0 in 2024, then soared by 76.48% to -$858.0 in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$858.0, -$3648.0, and $122.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -858.00 |
| Mar 31, 2025 | -858.00 |
| Dec 31, 2024 | -3,648.00 |
| Dec 31, 2024 | -3,648.00 |
| Sep 30, 2024 | 122.00 |
| Sep 30, 2024 | 122.00 |
| Jun 30, 2024 | -10,805.00 |
| Jun 30, 2024 | -10,805.00 |
| Mar 31, 2024 | -10,039.00 |
| Mar 31, 2024 | -10,039.00 |
| Dec 31, 2023 | -209,738.00 |
| Dec 31, 2023 | -209,738.00 |
| Sep 30, 2023 | -67,822.00 |
| Sep 30, 2023 | -67,822.00 |
| Jun 30, 2023 | 233,821.00 |
| Jun 30, 2023 | 233,821.00 |
| Mar 31, 2023 | -50,657.00 |
| Mar 31, 2023 | -50,657.00 |
| Dec 31, 2022 | -469,722.00 |
| Dec 31, 2022 | -469,722.00 |